STAT Therapeutics Completes ACCEL-KS Grant for D-CUFF™ Development

‍ ‍

We're excited to announce the successful completion of our ACCEL-KS grant project.

The support provided through ACCEL-KS enabled our team to achieve two important development milestones:

·       Completion of our next-generation D-Cuff® prototype

·       Validation of our first product selection for the D-Cuff platform

These accomplishments represent meaningful progress toward commercializing D-Cuff®, our first-in-class drug-device combination engineered to enable consistent, user-friendly intramuscular (IM) delivery in non-clinical settings. Our goal is to make emergency and time-sensitive injectable therapies more accessible to patients, caregivers, and other laypersons when and where they are needed most.

We extend our sincere appreciation to KU Innovation Park and the Kansas Department of Commerce for their commitment to fostering early-stage life sciences innovation in Kansas. Programs like ACCEL-KS provide critical support that helps emerging companies transform promising technologies into solutions with the potential to improve patient care.

We're grateful for this partnership and look forward to the next phase of D-Cuff development as we continue advancing toward clinical and commercial milestones.

About STAT Therapeutics
STAT Therapeutics is a Kansas-based life sciences company focused on bringing accessible, high-impact medical technologies to patients and caregivers. The company’s lead innovation, D-CUFF™, is designed to enable immediate and reliable IM drug delivery outside of traditional healthcare settings, expanding access to critical treatments. For more information, visit www.stattherapeutics.com.

‍

#STATTherapeutics #DCuff #DrugDeviceCombination #MedTech #Biotech #LifeSciences #MedicalInnovation #HealthcareInnovation #KansasInnovation #ACCELKS #KUInnovationPark #KansasDepartmentofCommerce #IntramuscularInjection #DrugDelivery

‍ ‍